PRIMARY OBJECTIVES:~I. All cohorts: Safety of 68Ga-FAP-2286.~II. Cohort 1: Measured uptake of radiotracer (SUVpeak) in regions of known liver fibrosis.~III. Cohort 2: Measured uptake of radiotracer (SUVpeak) in regions of known pulmonary fibrosis.~IV. Cohort 3: Measured uptake of radiotracer (SUVpeak) in regions of myocardial fibrosis.~EXPLORATORY OBJECTIVES:~I. Correlation of 68Ga-FAP-2286 uptake with FAP expression determined by immunohistochemistry.~II. Compare 68Ga-FAP-2286 scan results to archival Computerized tomography (CT), magnetic resonance imaging (MRI), or Positron Emission Tomography (PET) images.~Patients will receive a single administration of 68Ga-FAP-2286 prior to PET imaging and will be followed for up to two hours after the injection of 68Ga-FAP-2286 for evaluation of adverse events.
This is a single arm prospective pilot trial that evaluates the ability of a novel imaging agent (68Ga-FAP-2286) to identify pathologic fibrosis in the setting of hepatic, cardiac and pulmonary fibrosis.~FAP-2286 is a peptide that potently and selectively binds to Fibroblast Activation Protein (FAP). FAP is a transmembrane protein expressed on fibroblasts and has been shown to have higher expression in idiopathic pulmonary fibrosis (IPF), cirrhosis, and cardiac fibrosis.